What is the Y-BOCS scale used in OCD trials?

The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is the primary validated outcome measure used in OCD clinical research. It measures symptom severity across obsessions and compulsions on a 0–40 scale. A reduction of 35% or more is generally considered clinically significant.

What OCD clinical trials are underway in 2026?

Active and recently completed trials include: (1) Yale/Columbia double-blind RCT (NCT03356483) — confirmed clinically significant OCD symptom reductions at 48 hours vs placebo; (2) Yale Phase 2 double-blind trial (NCT05546658) — psilocybin 0.25 mg/kg vs niacin placebo with fMRI component; (3) Imperial College London pharmacological challenge — 10 mg psilocybin, results published July 2025.

Is psilocybin legal for OCD treatment in the US?

Psilocybin is Schedule I federally and has no FDA approval for OCD. Legal access in 2026 is via clinical trial enrollment only. Oregon and Colorado's licensed psilocybin programs permit adult use without a specific diagnosis requirement, so supervised use for OCD-related distress may be accessed through those regulated programs, though they are not clinical treatment protocols.

Editorial: Written by Chief Bear, editorial lead · Medically informed review: claims are checked against primary literature cited on this page. This is educational content, not personal medical advice.

🔄 Clinical Evidence

Psilocybin for OCD: Evidence, Mechanism & Clinical Trials

Q: Can psilocybin treat OCD?

Emerging clinical evidence suggests psilocybin may meaningfully reduce OCD symptoms. A 2006 double-blind study (Moreno et al., University of Arizona) found 23–100% reductions in Y-BOCS scores across dosing sessions in 9 patients. A 2024 randomized, double-blind placebo-controlled trial (Yale/Columbia) showed clinically significant mean reductions in OCD symptoms at 48 hours post-dosing vs placebo. A 2025 pharmacological challenge study (Imperial College London) found a moderate-to-large effect on compulsive symptoms lasting up to one week after a 10 mg dose. Psilocybin is not FDA-approved for OCD and is currently accessible only via clinical trials.

Q: How does psilocybin help with OCD?

OCD is characterized by hyperactivity in the cortico-striato-thalamo-cortical (CSTC) circuit — a feedback loop involving the orbitofrontal cortex, striatum, thalamus, and anterior cingulate cortex that becomes locked in compulsive patterns. Psilocybin's agonism at 5-HT2A receptors appears to disrupt this overactive loop, normalise fronto-striatal functional connectivity, and reduce activation in the anterior cingulate cortex and amygdala in response to OCD-triggering stimuli.

OCD affects 2–3% of the global population. SSRIs and CBT help only a fraction of patients. Here's what the emerging trial data shows about psilocybin as a treatment for treatment-refractory OCD — and why the mechanism is neurologically distinct from its effects on depression.

Chief Bear

Updated March 14, 2026 · 7 min read

Quick Answer

Three independent lines of clinical evidence now show psilocybin produces meaningful, rapid reductions in OCD symptom severity — including in patients who have failed SSRIs and CBT. A 2024 Yale/Columbia randomised controlled trial confirmed clinically significant reductions vs placebo at 48 hours. Psilocybin is not FDA-approved for OCD, has no Breakthrough Therapy designation for this indication, and is accessible only via clinical trial enrollment in 2026. Evidence level: Early–Emerging.

What the Research Shows

OCD affects an estimated 1 in 40 adults in the US. Standard treatments — SSRIs and cognitive-behavioural therapy with exposure and response prevention (CBT/ERP) — produce remission in only 40–60% of patients. For the remainder, few options exist. This treatment gap has driven growing interest in psilocybin, which acts on the same serotonergic system implicated in OCD but through a fundamentally different mechanism than daily SSRIs.

23–100%Y-BOCS score reduction rangeMoreno et al., University of Arizona, 2006

✓ RCTClinically significant vs placeboYale/Columbia trial, closed May 2024

1 wkSymptom reduction durationImperial College London, 2025

4+Active or completed trialsClinicalTrials.gov, 2026

Study	Design	Key Finding	Evidence
Moreno et al., 2006 University of Arizona	Modified double-blind, 9 patients, 4 dose levels	23–100% Y-BOCS reductions across sessions; all patients showed marked decrease in ≥1 session; improvements persisted beyond 24 hours	Emerging
Kelmendi et al., 2024 Yale / Columbia	RCT, double-blind, niacin placebo-controlled; closed enrollment May 2024	Clinically significant mean OCD symptom reductions in psilocybin group vs placebo at 48-hour primary endpoint	Emerging
Browning et al., 2025 Imperial College London	Pharmacological challenge, 10 mg psilocybin, no randomisation	Well-tolerated; moderate-to-large effect on compulsive symptoms; reductions lasting up to one week post-dosing	Early
Yale Phase 2 Trial NCT05546658, ongoing	Double-blind RCT; 0.25 mg/kg psilocybin vs niacin; 30 participants; fMRI neuroimaging component	Recruiting; will assess fronto-striatal connectivity changes alongside clinical outcomes	Early

How Psilocybin May Help OCD

Understanding psilocybin's potential in OCD requires understanding what goes wrong in OCD neurobiology. The condition is characterised by dysregulation of the cortico-striato-thalamo-cortical (CSTC) circuit — a neural feedback loop connecting the orbitofrontal cortex, caudate nucleus, thalamus, and anterior cingulate cortex. In OCD, this circuit becomes hyperactive and locked: intrusive thoughts trigger compulsive behaviours, which temporarily relieve anxiety, which reinforces the loop.

Why psilocybin may disrupt the CSTC loop

Psilocybin's active metabolite psilocin acts as a partial agonist at serotonin 5-HT2A receptors concentrated in the prefrontal cortex. Research from the Yale/Columbia trial team hypothesises three mechanisms:

Normalisation of fronto-striatal connectivity — psilocybin may restore the hyperactive orbitofrontal-striatal signalling to a more balanced baseline
Reduced anterior cingulate and amygdala reactivity — psilocybin appears to decrease activation of these regions in response to OCD-triggering stimuli, measured via fMRI at 48 hours post-dosing
Neuroplasticity window — as with depression and PTSD, the neuroplasticity enhancement following a psilocybin session may allow entrenched compulsive thought patterns to be disrupted and restructured during post-session integration work

Important distinction

Unlike OCD's standard SSRI treatment — which works by increasing serotonin availability chronically — psilocybin's proposed mechanism is circuit-level disruption of the overactive CSTC loop in a single acute session. This may explain why some patients whose OCD failed to respond to SSRIs show responses to psilocybin: the two treatments act through different nodes of the same system.

Clinical Trials: What's Been Done & What's Active

1. Moreno et al. (2006) — First Modern OCD Trial Emerging

Published in the Journal of Clinical Psychiatry, this was the first controlled clinical study of psilocybin in OCD patients. Nine participants received up to four single-dose exposures at sub-hallucinogenic to frankly hallucinogenic doses (25–300 µg/kg), in a modified double-blind design. All nine participants showed marked symptom decreases — ranging from 23% to 100% reductions on the Y-BOCS — in at least one session. Importantly, no significant dose-response relationship was found: lower doses sometimes produced results comparable to higher ones, a pattern that has since been replicated and raises questions about the mechanism.

2. Yale/Columbia RCT (2018–2024) — First Double-Blind Placebo-Controlled Trial Emerging

Led by Dr. Benjamin Kelmendi and Dr. Christopher Pittenger, this trial (NCT03356483) enrolled participants with treatment-refractory OCD — defined as having failed at least one adequate SSRI and/or CBT trial. Participants received a single moderate dose of psilocybin (0.25 mg/kg) or niacin as active placebo, with non-directive psychological support. The trial closed to enrollment in May 2024. Published results (Frontiers in Psychiatry, 2025) confirmed clinically significant mean reductions in OCD symptoms in the psilocybin group vs placebo at the 48-hour primary endpoint. Full quantitative results and follow-up data are anticipated in peer-reviewed publication in 2026.

3. Imperial College London (2025) — Pharmacological Challenge Early

Published in the Journal of Psychiatric Research (2025), this study administered two sequential doses of oral psilocybin (1 mg then 10 mg, four weeks apart) to patients with moderate-to-severe OCD. The 10 mg dose was well-tolerated and produced a rapid-onset moderate-to-large effect on compulsive symptoms, lasting up to one week after dosing. The authors note this study was limited by small sample size and absence of randomisation, and called for larger RCTs.

4. Yale Phase 2 Trial (Ongoing, 2026) Early

A second Yale trial (NCT05546658) is currently recruiting 30 participants for a double-blind, niacin-controlled study of 0.25 mg/kg psilocybin for treatment-refractory OCD, with an embedded fMRI component to measure fronto-striatal connectivity changes 48 hours post-dosing. This study will provide the first neural biomarker data on psilocybin's mechanism in OCD.

Psilocybin vs. Standard OCD Treatments

Standard first-line OCD treatment consists of two modalities: SSRIs (particularly fluvoxamine, sertraline, and fluoxetine at high doses) and cognitive-behavioural therapy with exposure and response prevention (CBT/ERP). Both have significant limitations.

The gap psilocybin is targeting

SSRI response rates: approximately 40–60% of OCD patients respond to SSRIs; fewer than 20% achieve full remission (Soomro et al., 2008)
CBT/ERP response rates: effective for 50–60% of patients who complete treatment, but dropout is high due to the distress of prolonged exposure exercises
Treatment-resistant OCD: an estimated 25–40% of OCD patients fail both SSRIs and adequate CBT — this is the population psilocybin trials have focused on

All current psilocybin OCD trials require participants to discontinue SSRIs before dosing, due to the well-documented blunting effect of 5-HT2A receptor desensitisation. See Microdosing on SSRIs for the pharmacology of this interaction.

No head-to-head trial yet

No published study has directly compared psilocybin with SSRIs or CBT/ERP for OCD. The existing evidence establishes that psilocybin produces meaningful symptom reductions in patients who have already failed standard treatments — it does not establish superiority to those treatments as a first-line option.

Who May Be a Candidate

Based on trial eligibility criteria, psilocybin for OCD has been studied in adults who meet the following profile:

Confirmed DSM-5 diagnosis of OCD, established by clinical interview (MINI or equivalent)
OCD of at least moderate severity on the Y-BOCS
Failed at least one adequate trial of SSRI medication at therapeutic dose for ≥12 weeks
Able and willing to discontinue SSRIs for the study period (under clinical supervision)
No personal or family history of psychosis, schizophrenia, or bipolar I disorder
No active suicidality, current substance use disorder, or significant cardiovascular disease

Contraindication note

Psilocybin is contraindicated in individuals with personal or family history of psychosis. OCD has a moderate lifetime comorbidity with psychotic features in some presentations — screening for this is a critical clinical gatekeeping step in all psilocybin OCD trials.

Access in 2026

Psilocybin is not FDA-approved for OCD and has not received Breakthrough Therapy designation for this indication. Legal access pathways in 2026 are limited:

Clinical trial enrollment

The primary legal access route. Active and recruiting trials can be found at clinicaltrials.gov — search "psilocybin OCD." Yale's ongoing Phase 2 trial (NCT05546658) is the most advanced US-based study currently recruiting. Participation is free; participants typically receive compensation for time and travel.

Oregon and Colorado licensed programs

Oregon and Colorado's state-licensed psilocybin programs permit supervised use by adults without requiring a specific diagnosis. While these programs are not clinical OCD treatment protocols, adults with OCD-related distress who do not qualify for trials may access supervised sessions through licensed facilitators in these states. This is not a medical treatment — it is supervised personal use within a legal framework. See Legal Status and Retreats for access details.

What to expect in sessions

All psilocybin OCD trials use a preparation, dosing session, and integration structure. Participants receive non-directive or supportive psychological accompaniment rather than OCD-specific exposure therapy during the session. The psilocybin therapy guide covers the 3-phase protocol in full.

Frequently Asked Questions

Can psilocybin treat OCD?

Emerging evidence says yes, particularly for treatment-refractory OCD. Three independent trials — Arizona (2006), Yale/Columbia (2024), and Imperial College London (2025) — have shown meaningful OCD symptom reductions following psilocybin. Psilocybin is not FDA-approved for OCD and clinical trial enrollment is currently the only regulated access pathway.

How does psilocybin help with OCD?

OCD is driven by hyperactivity in the CSTC circuit — a brain feedback loop involving the orbitofrontal cortex, striatum, and thalamus. Psilocybin's 5-HT2A agonism appears to disrupt this overactive loop, normalise fronto-striatal connectivity, and reduce reactivity in the anterior cingulate cortex and amygdala in response to OCD-triggering stimuli. This is mechanistically distinct from how SSRIs work in OCD.

What is the Y-BOCS, and what do trial results mean?

The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is the primary validated outcome measure for OCD research. It measures symptom severity on a 0–40 scale. A reduction of 35%+ is generally considered clinically significant. The 2006 Arizona trial showed 23–100% reductions; the 2024 Yale RCT confirmed clinically significant reductions vs placebo.

Is psilocybin better than SSRIs for OCD?

No direct comparison trial exists. Psilocybin's evidence for OCD specifically targets treatment-resistant cases where SSRIs have already failed — not as a first-line replacement. SSRIs remain the standard first-line pharmacological treatment. Note that SSRIs must be discontinued before psilocybin dosing due to 5-HT2A blunting.

What OCD trials are active in 2026?

The most advanced US trial is Yale's Phase 2 double-blind RCT (NCT05546658), studying 0.25 mg/kg psilocybin vs niacin with fMRI neuroimaging in 30 patients with treatment-refractory OCD. Full quantitative results from the Yale/Columbia RCT (closed May 2024) are expected in 2026 publication.

Is psilocybin for OCD legal in the US?

Psilocybin is Schedule I federally and not approved for OCD. Legal access is via clinical trial enrollment, or — without a specific OCD diagnosis requirement — through Oregon and Colorado's licensed supervised psilocybin programs. See Legal Status for the full map of access pathways.

Key Takeaways

→ Three independent trials now show psilocybin produces meaningful, rapid reductions in OCD symptoms — including a 2024 randomised, double-blind placebo-controlled trial at Yale/Columbia.
→ The proposed mechanism is CSTC circuit disruption — distinct from how SSRIs work — which may explain why some SSRI-refractory OCD patients respond to psilocybin.
→ A 2006 Arizona pilot found 23–100% reductions in Y-BOCS scores; a 2025 Imperial College study found moderate-to-large effects lasting up to one week after a 10 mg dose.
→ Psilocybin has no FDA Breakthrough Therapy designation for OCD. Clinical trial enrollment is the primary legal access pathway in 2026.
→ SSRIs must be discontinued before psilocybin dosing — 5-HT2A desensitisation from SSRIs significantly blunts effects. A supervised taper is required.